Boston-based medical provider of low-cost and next-gen wearable heart monitors, Cambridge Heartwear has announced the launch of its Artificial Intelligence-powered Heartsense monitor, this year. As per the reports, strokes in the U.S. are among the leading causes of death and heart disease is the leading slayer. Each year, stroke kills about 140,000 Americans, it shows 1 in every 20 deaths. Atrial Fibrillation (AF) or AFib, an asymmetrical heart rhythm that can lead to heart conditions like blood clots, stroke, and heart failure.
Cambridge Heartwear’s solution designed to detect AF and heart disease provides constant monitoring of heart rhythms through Electrocardiograms (ECGs) and the automatic interpretation and detection of irregularities utilizing AI. Its Heartsense monitor is the only wirelessly chargeable heart health device in the marketplace, which utilizes actual time, pulse oximetry and multiple ECG inputs. Patients, while using this device, control and own their own heart data. Patients can also enable the device to get and send out their real-time data to their physician. The Cambridge Heartwear’s device is already undertaken clinical trials among top-tier athletic organizations in the US and UK. The Cambridge Heartwear also offers Heartsense monitors to Indian and African communities to support ward off heart disease and stroke amongst patients, and the solution will be available in the marketplace by this year.
Founder and CEO of Cambridge Heartwear, Dr. Shakur stated that his company’s vision behind molding Cambridge Heartwear was to build a tailored and patient-driven solution to preventing stroke and heart disease. The AI healthcare sector is one of the rapidly growing marketplaces, and unlike other healthcare verticals that require investments; AI autonomously creating revenue and year over year growth. Back in the year 2014, AI healthcare was worth USD 600 million and is anticipated to reach USD 6.6 billion by 2021, with a staggering CAGR of 40 percent.